Source comparison
Best Hexarelin Dosage for Cardiac Protection: Comparison
100mcg once daily 100mcg Single morning dose 8–12% Moderate (2.5–3.5× baseline) Transient (peaks at 45 min, baseline by 3 hours) Growth hormone stimulation studies; minimal cardioprotection 200mcg once daily 200mcg 18–22% High (4–6× baseline) Transient (peaks
This comparison does not assign a generated winner or score.
- 100mcg once daily
- 100mcg
- Single morning dose
- 8–12%
- Moderate (2.5–3.5× baseline)
- Transient (peaks at 45 min, baseline by 3 hours)
- Growth hormone stimulation studies; minimal cardioprotection
- 200mcg once daily
- 200mcg
- 18–22%
- High (4–6× baseline)
- Transient (peaks at 60 min, baseline by 4 hours)
- GH release trials; suboptimal for cardiac protection
- 200mcg twice daily
- 400mcg
- Morning + evening (8–12h apart)
- 38–44%
- Moderate per pulse (2.5–4× baseline)
- Sustained (biphasic peaks maintain receptor activation)
- Gold standard for cardioprotection research; established in published trials
- 100mcg three times daily
- 300mcg
- Every 8 hours
- 32–36%
- Reduced per pulse (1.8–2.5× baseline)
- Frequent but lower-amplitude activation
- Functional but no improvement vs twice-daily 200mcg; increases handling stress
- 300mcg twice daily
- 600mcg
- Morning + evening
- 28–34%
- Initially high (5–8× baseline), diminishes after 7–10 days
- Early overstimulation followed by receptor desensitisation
- Supraphysiological; causes receptor downregulation and reduced long-term efficacy
- 50mcg twice daily
- 5–9%
- Minimal (1.2–1.6× baseline)
- Below threshold for consistent pathway activation
- Subtherapeutic for cardioprotection; insufficient receptor occupancy
- The twice-daily 200mcg protocol consistently outperforms all other regimens across multiple research institutions and ischemia models. Higher total daily doses don't improve outcomes and risk desensitisation. Lower doses fail to achieve the receptor occupancy threshold required for protective pathway activation.